Lipid Profile Changings After Switching From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine To Rilpivirine/Tenofovir Alafenamide/Emtricitabine: Different Effects In Patients With Or Without Baseline Hypercholesterolemia

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this retrospective multicentre study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/emtricitabine (FTC)/TDF to RPV/FTC/TAF in a cohort of HIV-1 infected patients. Total cholesterol (TC), high density lipoproteins (HDL) and low density lipoproteins (LDL) were compared at the moment of the switch and at the first following evaluation, by using paired t-test. Overall, 573 patients were considered, 99% with HIV-RNA < 50 copies/ml, with mean age of 49.7 (+/- 0.4) years and median 13.4 (6.9-22.5) years of HIV infection. In the study population with available data (431/573, 75%), mean TC changed from 173 +/- 1.7 to 188 +/- 1.8 mg/dl; mean HDL from 46 +/- 0.7 to 51 +/- 0.7 mg/dl; mean LDL from 111 +/- 1.5 to 120 +/- 1.8 mg/dl (p<0.0001 for all). Neither LDL/HDL nor TC/HDL ratio changed significantly, with LDL/HDL from 2.6 +/- 0.5 to 2.5 +/- 0.5 (p = 0.12) and TC/HDL from 4.0 +/- 0.6 to 3.9 +/- 0.6 (p = 0.11). In patients with baseline diagnosis of hypercholesterolemia (TC>200 mg/dl, N = 87), there was no significant change in TC (224 +/- 2.2 to 228 +/- 3.4 mg/dl, p = 0.286) or LDL (150 +/- 2.5 to 151 +/- 3.2 mg/dl, p = 0.751), while HDL increased from 51 +/- 1.6 to 55 +/- 1.7 mg/dl (p<0.0001) and both LDL/HDL and TC/HDL ratio decreased significantly, from 3.2 +/- 0.1 to 3.0 +/- 0.1 (p = 0.025) and from 4.7 +/- 0.1 to 4.4 +/- 0.1 (p = 0.004). In this real life study, a slight increase in lipids was found after switching from RPV/FTC/TDF to RPV/FTC/TAF, but these results were not confirmed in people with hypercholesterolemia, in which lipids did not change and LDL/HDL and TC/HDL ratio decreased.